Latest Content

Explore Alzheimer’s breakthroughs: lecanemab, donanemab, FDA blood tests, 2024 criteria, and new options to ease agitation and improve care.

Learn how clinicians reframe side effects, curb nocebo, and boost outcomes using expectation, open-label placebos, and conditioning in psychiatry.

Study of 470 BIPOC adults in residential care finds the Unified Treatment Model sustains reductions in eating disorder, depressive, and anxiety symptoms.

New Alzheimer trial news highlights safer anti-amyloid PMN310, cannabinoids easing agitation, tau gene therapy progress, FDA Fast Track psychosis drug, and TBI inflammation targets.

Experts discuss the impact of the placebo effect on psychiatric treatment outcomes.

Check out the pipeline updates from July!

Learn how an experienced psychiatrist structures first visits—from chief complaint to treatment plan—using empathic listening in telehealth or in person.

Retrospective cohort study of 1305 adults finds specialized virtual behavioral health care produced clinically meaningful gambling symptom improvement within 14 days.

FDA clears first triple reuptake ADHD drug Simtriyo, offering nonstimulant relief for adults and kids 6+ with executive and emotional symptoms.

From long-acting antipsychotics to psilocybin and new ADHD meds, clinicians weigh emerging therapies reshaping depression and postpartum care.

How can new Alzheimer therapies benefit patients today?

Emerging evidence shows eating disorders in male athletes are widely underrecognized, as screening tools built around female presentations overlook muscularity-driven behaviors like compulsive exercise, rigid dieting, and supplement misuse.

A first-in-vivo PET study finds M1 receptor availability reduced 13% to 19% across brain regions in schizophrenia, strengthening the case for muscarinic-targeted treatment.